Home > Oncology > ESMO 2020 > Breast Cancer > Second-line sacituzumab govitecan improves survival in metastatic TNBC

Second-line sacituzumab govitecan improves survival in metastatic TNBC


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
In pretreated metastatic TNBC patients, standard of care chemotherapy is associated with low objective response rates (ORRs) and short median progression-free survival (PFS). Results of the phase 3 ASCENT trial show improved ORR rates, and improved survival. Sacituzumab govitecan is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan. Trop-2 is expressed in all subtypes of breast cancer and linked to a poor prognoses. SN-38 is released both intracellularly and in the tumour microenvironment. Based on the results of a phase 1/2 trial, the FDA recently approved sacituzumab govitecan for treatment of refractory, metastatic TNBC [1]. In the phase 3 ASCENT study, 468 metastatic TNBC patients who had relapsed or had refractory disease after ≥2 prior chemotherapies in the advanced/metastatic setting were randomised 1:1 to sacituzumab govitecan (10 mg/kg IV on day 1 and 8, every 3 weeks) or s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on